Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study.
BACKGROUND
Bevacizumab provides clinical benefit in multiple solid tumours, but is associated with some increase in bleeding risk. Thrombotic events necessitating therapeutic anticoagulation (TA) are common in cancer. This report describes the safety of concurrent bevacizumab and TA in three large placebo-controlled clinical studies.


METHODS
Study 1 (metastatic colorectal cancer (mCRC)), study 2 (mCRC), and study 3 (advanced non-small cell lung cancer) were blinded phase III studies. Eligibility criteria excluded patients on TA. Patients on protocol treatment who developed thrombotic events requiring TA were permitted to continue bevacizumab or placebo under specified conditions. Adverse events in patients who received bevacizumab and TA concurrently were assessed using the NCI-CTCAE scale.


RESULTS
While experience is limited, venous thrombotic events were the most common reason for TA initiation in the three studies. Severe bleeding event rates for patients receiving TA in the bevacizumab-treated groups were similar in frequency to the placebo groups, ranging from 0 to 8% or 0 to 67 events per 100 patient-years. No severe pulmonary bleeding was reported in any of the TA-treated populations.


CONCLUSIONS
These data suggest that bevacizumab did not increase the risk of severe bleeding in cancer patients who received TA.
Division of Medical Oncology, Princess Margaret Hospital, 5th Floor Room 105, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada. Natasha.leighl@uhn.on.ca
N B
NB
Leighl
J
J
Bennouna
J
J
Yi
N
N
Moore
J
J
Hambleton
H
H
Hurwitz
D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000925:Anticoagulants / Q000627:therapeutic use*; D000068258:Bevacizumab; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D020246:Venous Thrombosis / Q000209:etiology / Q000517:prevention & control*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000925:Anticoagulants; D000068258:Bevacizumab
J Clin Oncol. 2007 Oct 20;25(30):4722-9
17947719
Lancet. 1996 Aug 17;348(9025):423-8
8709780
J Thromb Haemost. 2007 Mar;5(3):632-4
17319909
J Clin Oncol. 2009 Mar 10;27(8):1227-34
19188680
Clin Appl Thromb Hemost. 2006 Oct;12(4):389-96
17000884
Lancet Oncol. 2010 Aug;11(8):733-40
20650686
J Clin Oncol. 2008 Nov 20;26(33):5326-34
18854571
Semin Radiat Oncol. 2003 Jul;13(3):176-81
12903007
J Clin Oncol. 2005 Jun 1;23(16):3697-705
15738537
N Engl J Med. 2003 Jul 10;349(2):146-53
12853587
J Clin Oncol. 2008 Apr 20;26(12):2013-9
18421054
Mayo Clin Proc. 1995 Aug;70(8):725-33
7630209
J Clin Oncol. 2007 Dec 1;25(34):5490-505
17968019
Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):13-47
10758303
J Clin Oncol. 2009 Oct 1;27(28):4733-40
19720927
Lancet. 2007 Dec 22;370(9605):2103-11
18156031
N Engl J Med. 2006 Dec 14;355(24):2542-50
17167137
N Engl J Med. 2004 Jun 3;350(23):2335-42
15175435
J Clin Oncol. 2004 Jun 1;22(11):2184-91
15169807
N Engl J Med. 2007 Dec 27;357(26):2666-76
18160686
Arch Intern Med. 2000 Mar 27;160(6):809-15
10737280
J Clin Oncol. 2000 Sep;18(17):3078-83
10963635